These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 12814975)

  • 1. A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives.
    Locuson CW; Wahlstrom JL; Rock DA; Rock DA; Jones JP
    Drug Metab Dispos; 2003 Jul; 31(7):967-71. PubMed ID: 12814975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative binding models for CYP2C9 based on benzbromarone analogues.
    Locuson CW; Rock DA; Jones JP
    Biochemistry; 2004 Jun; 43(22):6948-58. PubMed ID: 15170332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
    Peng CC; Rushmore T; Crouch GJ; Jones JP
    Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant.
    Hummel MA; Locuson CW; Gannett PM; Rock DA; Mosher CM; Rettie AE; Tracy TS
    Mol Pharmacol; 2005 Sep; 68(3):644-51. PubMed ID: 15955872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9).
    Davies C; Witham K; Scott JR; Pearson A; DeVoss JJ; Graham SE; Gillam EM
    Drug Metab Dispos; 2004 Apr; 32(4):431-6. PubMed ID: 15039296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles.
    Kumar V; Locuson CW; Sham YY; Tracy TS
    Drug Metab Dispos; 2006 Oct; 34(10):1688-96. PubMed ID: 16815961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.
    Melet A; Marques-Soares C; Schoch GA; Macherey AC; Jaouen M; Dansette PM; Sari MA; Johnson EF; Mansuy D
    Biochemistry; 2004 Dec; 43(49):15379-92. PubMed ID: 15581350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.
    Ahlström MM; Ridderström M; Zamora I
    J Med Chem; 2007 Nov; 50(22):5382-91. PubMed ID: 17915853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes.
    Uchida S; Shimada K; Misaka S; Imai H; Katoh Y; Inui N; Takeuchi K; Ishizaki T; Yamada S; Ohashi K; Namiki N; Watanabe H
    Drug Metab Pharmacokinet; 2010; 25(6):605-10. PubMed ID: 20962433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9.
    Hummel MA; Tracy TS; Hutzler JM; Wahlstrom JL; Zhou Y; Rock DA
    J Biomol Screen; 2006 Apr; 11(3):303-9. PubMed ID: 16490777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes.
    McGinnity DF; Tucker J; Trigg S; Riley RJ
    Drug Metab Dispos; 2005 Nov; 33(11):1700-7. PubMed ID: 16081671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore.
    Egnell AC; Eriksson C; Albertson N; Houston B; Boyer S
    J Pharmacol Exp Ther; 2003 Dec; 307(3):878-87. PubMed ID: 14557374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of CYP2C9 inhibition by flavones and flavonols.
    Si D; Wang Y; Zhou YH; Guo Y; Wang J; Zhou H; Li ZS; Fawcett JP
    Drug Metab Dispos; 2009 Mar; 37(3):629-34. PubMed ID: 19074529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9.
    Zamora I; Afzelius L; Cruciani G
    J Med Chem; 2003 Jun; 46(12):2313-24. PubMed ID: 12773036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
    Afzelius L; Zamora I; Masimirembwa CM; Karlén A; Andersson TB; Mecucci S; Baroni M; Cruciani G
    J Med Chem; 2004 Feb; 47(4):907-14. PubMed ID: 14761192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors.
    Locuson CW; Suzuki H; Rettie AE; Jones JP
    J Med Chem; 2004 Dec; 47(27):6768-76. PubMed ID: 15615526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: the molecular basis of substrate binding and regioselectivity toward warfarin.
    Seifert A; Tatzel S; Schmid RD; Pleiss J
    Proteins; 2006 Jul; 64(1):147-55. PubMed ID: 16639745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I.
    Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
    Curr Drug Metab; 2009 Dec; 10(10):1075-126. PubMed ID: 20167001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors.
    Ahlström MM; Ridderström M; Zamora I; Luthman K
    J Med Chem; 2007 Sep; 50(18):4444-52. PubMed ID: 17696334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates.
    Sykes MJ; McKinnon RA; Miners JO
    J Med Chem; 2008 Feb; 51(4):780-91. PubMed ID: 18237107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.